Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC and AstraZeneca Scoop Prestigious SCRIP Award

Published: Tuesday, December 04, 2012
Last Updated: Tuesday, December 04, 2012
Bookmark and Share
The innovative collaboration between the Medical Research Council and AstraZeneca has won the ‘Best Partnership Alliance’ award at the annual SCRIP Awards.

The AZ-MRC alliance broke new ground in the way industry collaborates with academia and government to share knowledge and discover and develop new drugs.

Clive Morris, AstraZeneca Vice President, New Opportunities iMed, said:

“We are deeply honoured that our alliance with the MRC has been singled out for its innovative character. This is especially meaningful because our alliance with the MRC has played a leading role in inspiring a new era of collaboration and open innovation in the industry.”

Dr Chris Watkins, Head of Translational Research and Industry Liaison at the MRC, who accepted the award, said:

"It's been an absolute pleasure to work with AstraZeneca throughout our ground-breaking compound collaboration and we feel we've made a real step forward in the way we collaborate with industry. We were really pleased with the quality of science we funded through the partnership and to have this all recognised by a prestigious SCRIP award is the icing on the cake, we're delighted to have won."

SCRIP is one of the world’s leading pharmaceutical and biotech news organisations and its ‘Best Partnership Alliance’ award recognises the importance of partnerships involving pharmaceutical and/or biotech companies in developing novel therapeutics.

The ceremony, which took place on 28 November at London’s Lancaster Hotel, rewarded excellence over the whole range of industry activities, from pharma, biotech and those companies that support them.

The AZ-MRC alliance, in which 22 previously studied AstraZeneca compounds were made available to academic researchers, was announced in December 2011. Since then, the MRC and AstraZeneca have announced £7 million funding for 15 research projects involving those compounds.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Technology, Alzheimer’s Association Collaborate
MRC Technology (MRCT), an independent medical research charity based in London, and the Alzheimer’s Association in Chicago have entered into an agreement to review and monitor the Association’s grant-funded research portfolio.
Thursday, January 21, 2016
Study Identifies New Way to Kill the Malaria Parasite
Scientists have discovered new ways in which the malaria parasite survives in the blood stream of its victims, a discovery that could pave the way to new treatments for the disease.
Tuesday, July 07, 2015
AstraZeneca, MRC Collaboration to Create New Centre for Early Drug Discovery
The Companies today announced the groundbreaking collaboration aimed at better understanding the mechanisms of human disease. The collaboration will see the creation of a joint research facility at AstraZeneca’s new R&D centre in Cambridge in the UK.
Monday, March 31, 2014
Scientists Edge Closer Towards First Pancreatitis Treatment
Scientists have provided proof of principle for a drug-based treatment of acute pancreatitis – a disease for which currently there is no treatment.
Friday, July 26, 2013
MRC Delivering on the Life Sciences Strategy, One Year On
The Medical Research Council has made significant progress in implementing the measures outlined in last year’s Strategy for UK Life Sciences, according to a progress update published by the Government.
Tuesday, December 11, 2012
A Phenomenal Legacy for London 2012
The Phenome Centre will use the cutting edge facilities developed for London 2012 to help develop better and more targeted treatment for patients.
Wednesday, August 01, 2012
Scientific News
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Honey’s Potential to Save Lives
The healing powers of honey have been known for thousands of years.
3-D Printed Lifelike Liver Tissue for Drug Screening
A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!